Skip to main content
S&P 5007,551.81-0.45%DOW51,461.90-1.21%NASDAQ25,978.42-0.01%BTC$76,346.00+0.85%ETH$2,420.07+0.87%GOLD$4,327.00-1.38%OIL$101.32-1.08%
Smart Investors Daily
ST

NASDAQ · STSA

Satsuma Pharmaceuticals, Inc.

Healthcare · Biotechnology

$1.10

Up+$0.00 (+0.00%)

Updated Sep 17, 2026, 9:14 AM

SID Score

—

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
36.47M
P/E ratio
-0.51
Dividend yield
0.00%
52-week range
— – —
Volume
1.83M
Avg. volume
1.21M

Price performance

STSA price history

1M range · 0 trading sessions · Daily adjusted prices

STSA does not have enough price history for the selected period.

Data unavailable

Market data is busy. Please try again shortly.

Latest STSA news

The latest Smart Investors Daily articles mentioning STSA.

Stock researchCompany · Overview

STSA research

Overview

Company profile and research snapshot.

Company profile

Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. The company's lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in SUMMIT Phase 3 efficacy trials and can be self-administered with proprietary pre-filled, single-use, and nasal delivery device. Satsuma Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
—
Implied upside
—
Analysts
11
STSA recent ratings
DateFirmRatingTarget
Apr 18, 2023HC Wainwright & Co.Neutral—
Mar 30, 2023MizuhoNeutral—
Mar 30, 2023HC Wainwright & Co.Buy—
Nov 15, 2022MizuhoNeutral—
Nov 15, 2022SVB LeerinkMarket Perform—
Open full forecast

News briefing

No generated briefing is available yet.

prnewswire.com · Nov 5, 2025

Satsuma Pharmaceuticals and SNBL Announce Publication of Impression of Use and Satisfaction with STS101 (Dihydroergotamine Nasal Powder (Atzumi™)) in Headache

Results show that participant impression through 12 months of treatment indicate STS101 is perceived as favorable across multiple attributes. Exploratory Efficacy Endpoints showed that STS101 provided rapid freedom from pain, from most bothersome symptoms at 2 hours and sustained treatment benefits over 48 hours after dosing.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By